Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin (BCG) Tice, the active ingredient in Oncotice, is a live attenuated bacterial vaccine presented as a powder for intravesical use. It treats non‑muscle‑invasive bladder cancer in adults. GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

Oncotice is a live attenuated bacterial vaccine used in the management of bladder cancer, acting on the urothelial lining to stimulate an immune response.

- Non‑muscle‑invasive bladder cancer (NMIBC): Reduces recurrence and progression after transurethral resection. - Carcinoma in situ of the bladder: Provides local immunotherapy to eradicate tumor cells. - High‑risk NMIBC: Used as maintenance therapy to prolong disease‑free intervals.

Oncotice may cause a range of adverse reactions, most of which are local to the bladder and some systemic.

Common Side Effects: - Cystitis‑like symptoms: dysuria, urgency, frequency. - Hematuria: mild to moderate blood in urine. - Low‑grade fever and chills. - Fatigue or malaise. - Mild abdominal discomfort.

Serious or Rare Side Effects: - Systemic BCG infection (disseminated mycobacterial disease). - Severe allergic reactions including anaphylaxis. - Persistent high‑grade fever. - Sepsis or septic shock. - Acute renal impairment. - Life‑threatening pneumonitis.

Before using Oncotice, clinicians should assess patient suitability and monitor for adverse events.

- Contraindication: Active tuberculosis or untreated Mycobacterium infection. - Caution: Immunocompromised patients may have increased infection risk. - Monitor: Renal function should be evaluated before and during therapy. - Avoid: Recent urinary tract instrumentation or surgery may increase complications. - Pregnancy: Use only if clearly needed; potential fetal risk is unknown. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Oncotice can interact with other agents that modify immune function or cause overlapping toxicity.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent administration may increase risk of infection. - Systemic immunosuppressants (e.g., high‑dose steroids, biologics): may reduce BCG efficacy.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may alter BCG metabolism. - Chemotherapy agents given concurrently: increased bladder toxicity. - Anticoagulants: heightened risk of hematuria. - NSAIDs: may exacerbate renal side effects. - Cytokine‑targeting therapies: potential additive immune effects.